InflaRx N.V. Common Stock (IFRX)
InflaRx N.V. is a biopharmaceutical company focused on developing and commercializing therapies that target inflammatory diseases. The company's pipeline mainly includes monoclonal antibodies designed to inhibit the complement system's role in inflammatory processes, aiming to treat conditions such as hidradenitis suppurativa and other severe inflammatory disorders. Headquartered in the Netherlands, InflaRx leverages its expertise in immunology to develop innovative treatments for unmet medical needs.
Company News
InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.
InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to $0.6050 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Inspire Veterinary Partners, Inc. (NASDAQ: IVP) gaine...
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.